Biomedicine Daily · Tuesday, 20 October 2026

Filings, acceptances, designations, approvals and withdrawals at a regulator.

• satralizumabUpdateOn October 16, the FDA approved Roche's IL-6R monoclonal antibody satralizumab for thyroid eye disease (TED) in adults, introducing IL-6R as a new targeted mechanism for the indication and ending six years of exclusivity for the IGF-1R drug Tepezza. Satralizumab is also a TED therapy that can be self-administered by subcutaneous injection at home, adding a mechanism and delivery option beyond IGF-1R.FDA
• AnktivaUpdateThe FDA has approved Anktiva for patients with BCG-unresponsive, high-grade papillary-only non-muscle invasive bladder cancer (NMIBC), making it the first approved therapy for this population. The source says the approval marks a new FDA approach to evaluating therapies for BCG-unresponsive NMIBC, and notes that CIS is always high-grade while papillary tumors can be low-grade or high-grade.FDA
• Novo Nordisk's IcoSema First to Win China Approval for PostUpdateNovo Nordisk announced on October 15 that the NMPA has approved the market application of NovoJect (icoSema, insulin icodec and semaglutide injection) for the Post-OADs indication, adding adults with type 2 diabetes inadequately controlled on prior oral antidiabetic drugs. The approval is based on COMBINE 4, a randomized, open-label phase 3b trial enrolling 485 patients that compared once-weekly icoSema with once-daily insulin glargine U100.NMPA

Trial starts, early and mid-stage data, and results that did not make the daily.

• HARMONiUpdateAt the 2026 WCLC, the HARMONi-2 study presented updated overall survival data for ivonescimab versus pembrolizumab as first-line treatment for PD-L1-positive advanced NSCLC, showing a median OS of 30.8 months and a statistically significant, clinically meaningful positive OS result. Professor Chu Qian's interpretation noted consistent benefit across subgroups, with median OS exceeding three years in patients with high PD-L1 expression.
• Toripalimab Consolidation in LimitedUpdateThe full results of the GASTO-1052A study were published in the Journal for ImmunoTherapy of Cancer (JITC, IF=11.7). Toripalimab consolidation therapy significantly prolonged progression-free survival versus observation in limited-stage small cell lung cancer (LS-SCLC), with a PFS hazard ratio of 0.55.
• More than half of people with earlyUpdateThe RESET for Remission trial enrolled 96 patients with early-onset type 2 diabetes, average age 38. After a 24-week program (12 weeks of an 800–900 kcal/day low-energy diet plus supervised strength and aerobic training, followed by a 12-week maintenance phase), about 54% achieved remission without medication, versus 4% in the control group.
• Doxycycline PEP Loses Effect Against GonorrheaUpdateReal-world data from more than 26,000 people in Southern California followed for two years show that doxycycline PEP protection against gonorrhea fell to zero between roughly 11 and 14 months after rollout, while the share of gonorrhea samples in regional surveillance carrying the TETM resistance gene rose from 22% to 59%; over the same period chlamydia infections fell 66.5% and syphilis 60.7%. The authors state that the correlation cannot directly prove PEP caused the rise in resistance, recommend no longer using doxycycline PEP for gonorrhea prevention, and note that protection against chlamydia and syphilis persisted throughout the study period.
• taladegibUpdateEndeavor's Hedgehog pathway inhibitor taladegib (ENV-101) met the ppFVC primary endpoint in the WHISTLE-PF phase 2b trial in IPF, and the company plans to advance to phase 3. The trial enrolled 213 patients across 74 centers in 14 countries, with results announced on 2026-10-08. The poster views the mechanism, which differs from existing pirfenidone and nintedanib, as a potential threat to current IPF therapies, though phase 2b success does not guarantee phase 3 success or approval.
• Argenx Stops LateUpdateOn October 8, Argenx announced discontinuation of UNITY, its late-stage trial of efgartigimod in Sjogren's syndrome. The company's shares fell 12% in a single day, and its market value dropped back to $51.2 billion. The article uses the case to discuss the structural fragility of single-product dependence in the autoimmune field.
• Aerovius ThirdUpdateAerovius (Ailisi) announced that results of the FURTHER phase 1b study (FURMO-002) of its self-developed third-generation EGFR-TKI furmonertinib have been published in the international journal Cancer Cell. The results show its potential as an oral, chemotherapy-free targeted therapy for treatment-naive advanced EGFR PACC-mutant non-small cell lung cancer. EGFR PACC mutations account for about 12% of EGFR-mutant tumors, and no established targeted standard of care exists.
• Fabhalta（iptacopan）UpdateNovartis has terminated a Phase 2 study of Fabhalta (iptacopan) in lupus nephritis, saying the decision was based on strategic considerations and not on any efficacy or safety issues. The study enrolled 81 patients, and Novartis has completed the first part, whose primary endpoint was the complete renal response rate at week 24, but will not proceed with the second part. Iptacopan trials in other indications such as atypical hemolytic uremic syndrome and generalized myasthenia gravis will continue as planned, and Novartis remains active in lupus nephritis research through its investigational Phase 3 monoclonal antibody ianalumab.

Licensing, M&A and financing that did not make the daily.

• Estuary BiotherapeuticsUpdateEstuary Biotherapeutics has completed a $93 million Series A financing, equivalent to over 600 million yuan. RA Capital Management led the round, with participation from Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, and the National Kidney Foundation Innovation Fund.
• OrtetUpdateMedical AI startup Ortet, founded in New York this September, recently raised 500 million dollars even though its core product, the Ortet health model, is still in development with no public demo. The company positions the model as a patient-centered, multidimensional medical foundation model and is trying to build a native medical model from scratch, bypassing general-purpose large model foundations.